logo

For the Inventor, By the Inventor

Stevenage, United Kingdom

Sally Redshaw

This inventor holds 27 USPTO granted patents, primarily in HIV Protease Inhibitors. Top assignee: Hoffmann-La Roche Inc.. Active years: 1985-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sally Redshaw. Retrieved from https://idiyas.com/inventor/sally-redshaw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 27

% Patents Active = 92.6

Average Co-Inventor Count = 3.3

ph-index = 12

Forward Citations = 510(Granted Patents)


Location History:

  • Stevenage, GB (1987 - 1997)
  • Hitchin, GB (1985 - 2003)

Company Filing History:

goldMedal27 out of 5,028 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1985-2003

Loading Chart...
Areas of Expertise:
HIV Protease Inhibitors
Amino Acid Derivatives
Alcohols
Benzopyran Derivatives
Pyridazine Intermediates
Antihypertensive Compounds
Bicyclic Compounds
Pyrazolo Diazepines
27 patents (USPTO):Explore Patents
1. 6632826 - Carbocyclic HIV protease inhibitors (2003-10-14),
2. 6472404 - HIV protease inhibitors (2002-10-29),
3. 5652369 - Amino acid derivatives (1997-07-29),
4. 5620987 - Amino acid derivatives (1997-04-15),
5. 5580999 - Alcohols (1996-12-03),
6. 5571920 - Alcohols (1996-11-05),
7. 5554756 - Amino acid derivatives (1996-09-10),
8. 5516913 - Alcohols (1996-05-14),
9. 5508430 - Oxirane intermediates for novel alcohols (1996-04-16),
10. 5488115 - Alcohols (1996-01-30),
11. 5451678 - Alcohols (1995-09-19),
12. 5446161 - Amino acid derivatives (1995-08-29),
13. 5196438 - Amino acid derivatives (1993-03-23),
14. 5157041 - Amino acid derivatives (1992-10-20),
15. 5118694 - Benzopyran derivatives (1992-06-02),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I am pleased to offer you an article about the accomplished inventor Sally Redshaw.

Title: The Inventive Journey of Sally Redshaw: Pioneering HIV Protease Inhibitors

Introduction:

Sally Redshaw, a talented inventor hailing from Stevenage, GB, is renowned for her remarkable contributions to the field of pharmaceuticals and HIV treatment. With an impressive portfolio of 27 patents, Sally Redshaw's innovative work has significantly impacted the world of medicine.

Latest Patents:

Among her latest patents, one of the standout inventions is the Carbocyclic HIV protease inhibitors. This groundbreaking innovation involves novel isoquinoline carboxamide derivatives that serve as potent HIV protease inhibitors. These compounds hold immense promise in the treatment of HIV infections, showcasing Sally Redshaw's dedication to advancing healthcare solutions.

Career Highlights:

Sally Redshaw excels in her role at Hoffmann-La Roche Inc., a prominent pharmaceutical company known for fostering innovation and cutting-edge research. Her tenure at this esteemed organization has been marked by a series of groundbreaking inventions that have garnered attention within the scientific community.

Collaborations:

In her groundbreaking work, Sally Redshaw has collaborated closely with esteemed colleagues such as Gareth J Thomas and Geoffrey Lawton. Together, they have pushed the boundaries of scientific discovery, paving the way for new and improved treatments in the fight against HIV.

Conclusion:

In conclusion, Sally Redshaw's pioneering spirit and dedication to innovation have established her as a trailblazer in the field of pharmaceutical research. Her work not only showcases her remarkable talent but also highlights the profound impact that inventors like her can have on improving global health outcomes. Sally Redshaw's legacy as an inventor is sure to inspire future generations of innovators in the quest for groundbreaking solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…